ロード中...
Adalimumab in Psoriasis: How Much is Enough?
Biologic therapies targeting tumor necrosis factor have revolutionized treatment of immune-mediated inflammatory diseases such as psoriasis, but optimal dosing and appropriate use of therapeutic drug monitoring are not yet fully understood. Wilkinson et al. explore these questions in a real-world ps...
保存先:
| 出版年: | J Invest Dermatol |
|---|---|
| 主要な著者: | , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2019
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7357200/ https://ncbi.nlm.nih.gov/pubmed/30579425 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jid.2018.08.012 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|